By Deena Beasley (Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered ...

A Gilead Sciences-backed therapy made with a patient's own white blood cells shrank tumors in 62% of patients with recurrent ...

Shares of Gilead Sciences Inc. GILD slid 1.06% to $108.91 Monday, on what proved to be an all-around favorable trading ...

Gilead Sciences' TROP2-targeting drug Trodelvy is already used as a third-line treatment for PD-L1-positive triple-negative ...

The S&P 500 index closed higher on Monday as investors were still optimistic over trade talks between the United States and ...

In a flashback scene from Season 1, Episode 5, June sees four small girls dressed in red, oblivious that the color will be ...

Spoiler alert! Here's how Hulu's "The Handmaid's Tale" ends after six long seasons of June (Elisabeth Moss) in Gilead.

Citi analysts reiterated a Buy rating on Gilead Sciences, Inc. (NASDAQ:GILD) stock and maintained a $125 price target.

Gilead Sciences is well-positioned to continue to strengthen its position as a leader in the HIV therapy market. Learn more ...

This is the web version of STAT’s special newsletter from the annual meeting of the American Society of Oncology. For more ...

The Emmy-winning series 'The Handmaid's Tale' ended its six-season run on May 27, but a sequel project is in the works ...